[Drug metabolism in patients with liver disease (author's transl)].
Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital. This however could not been demonstrated in patients with intra- or extrahepatic cholestasis and patients with primary biliary cirrhosis of the liver. The plasma clearance of methohexital, - a high clearance drug - is not changed in the same way. Also there is no evidence as yet, that patients with liver disease and without a collateral portal circulation do have an increased bioavailability of oral high clearance drugs.
D000208:Acute Disease; D000328:Adult; D000983:Antipyrine / Q000378:metabolism*; D001682:Biological Availability; D001711:Biotransformation; D002779:Cholestasis / Q000378:metabolism; D005260:Female; D006505:Hepatitis / Q000378:metabolism; D006591:Hexobarbital / Q000378:metabolism*; D006801:Humans; D008012:Lidocaine / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D008723:Methohexital / Q000378:metabolism*; D008875:Middle Aged
D008012:Lidocaine; D006591:Hexobarbital; D008723:Methohexital; D000983:Antipyrine
Arzneimittelmetabolismus bei Patienten mit Lebererkrankungen.